Analyst consensus rating
ResMed Analyst Rating: Buy
RMD is rated Buy by 16 analysts with a $245.50 target. As of 2026-08-30.
Direct answer
ResMed's consensus rating is Buy.
16 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $245.50.
Forecast evidence checked August 30, 2026.
Get free ResMed email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $240.33
- Average price target
- $245.50
- High price target
- $320.00
- Low price target
- $175.00
- Low target gap
- -27.2%
- Target upside
- +2.2%
- High target gap
- +33.2%
- Target range width
- 60.3%
- Consensus rating
- Buy
- Analysts
- 16
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ResMed?
ResMed has a verified Buy consensus. The same dataset has an average price target of $245.50.
How far are ResMed's low and high targets from the recorded price?
The low target implies -27.2%, while the high target implies +33.2%.
How many analysts are included in ResMed's consensus?
The verified consensus includes 16 analysts.
How is ResMed's target upside or downside calculated?
The average target of $245.50 is divided by the recorded price of $240.33, then one is subtracted to produce +2.2%. This does not guarantee a future return.
When was ResMed's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.